<div id="readability-page-1"><div><p>As the Australian market navigates a period of slower trade and investor caution amid ongoing global tensions, identifying growth companies with significant insider ownership can offer valuable insights into potential investment opportunities. In this environment, where confidence is tempered by geopolitical uncertainties, stocks with strong insider commitment may signal a higher level of trust in the company's long-term prospects.</p><h3>Top 10 Growth Companies With High Insider Ownership In Australia</h3><table><tbody><tr><td><strong>Name</strong></td><td><strong>Insider Ownership</strong></td><td><strong>Earnings Growth</strong></td></tr><tr><td>Alfabs Australia (ASX:AAL)</td><td>10.8%</td><td>41.3%</td></tr><tr><td>Fenix Resources (ASX:FEX)</td><td>21.1%</td><td>47.8%</td></tr><tr><td>Cyclopharm (ASX:CYC)</td><td>11.3%</td><td>97.8%</td></tr><tr><td>Acrux (ASX:ACR)</td><td>15.5%</td><td>106.9%</td></tr><tr><td>Newfield Resources (ASX:NWF)</td><td>31.5%</td><td>72.1%</td></tr><tr><td>Echo IQ (ASX:EIQ)</td><td>19.8%</td><td>111.1%</td></tr><tr><td>Titomic (ASX:TTT)</td><td>11.2%</td><td>77.2%</td></tr><tr><td>Plenti Group (ASX:PLT)</td><td>12.7%</td><td>85%</td></tr><tr><td>Image Resources (ASX:IMA)</td><td>16.1%</td><td>127.3%</td></tr><tr><td>BETR Entertainment (ASX:BBT)</td><td>38.6%</td><td>77.5%</td></tr></tbody></table><p>Click here to see the full list of 93 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.</p><p>We're going to check out a few of the best picks from our screener tool.</p><h2>Aurelia Metals (ASX:AMI)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Aurelia Metals Limited is an Australian company involved in the exploration and production of mineral properties, with a market capitalization of A$456.99 million.</p><p><strong>Operations:</strong> The company's revenue is primarily derived from its operations at the Peak Mine (A$245.13 million), Dargues Mine (A$73.90 million), and Hera Mine (A$5.98 million).</p><p><strong>Insider Ownership:</strong> 23.9%</p><p>Aurelia Metals shows promise as a growth company with substantial insider ownership, evidenced by significant insider buying in recent months. The company has returned to profitability, reporting A$17.95 million net income for the half-year ending December 2024 compared to a loss previously. While gold and silver production declined, copper output increased significantly. Analysts forecast robust annual earnings growth of 23.6%, outpacing the broader Australian market's expected growth rate of 11.7%.</p><ul><li>Unlock comprehensive insights into our analysis of Aurelia Metals stock in this growth report.</li><li>The valuation report we've compiled suggests that Aurelia Metals' current price could be quite moderate.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/46a37689-ee1f-4def-96e3-c3eb839fa866/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/46a37689-ee1f-4def-96e3-c3eb839fa866/chart/earnings-and-revenue-growth"/><figcaption>ASX:AMI Earnings and Revenue Growth as at Apr 2025</figcaption></figure><h2>Clarity Pharmaceuticals (ASX:CU6)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> Clarity Pharmaceuticals Ltd is a clinical stage radiopharmaceutical company focused on research and development of radiopharmaceutical products in Australia and the United States, with a market cap of A$539.87 million.</p><p><strong>Operations:</strong> The company's revenue segment consists of Radiopharmaceutical Development, generating A$10.78 million.</p><p><strong>Insider Ownership:</strong> 17.8%</p><p>Clarity Pharmaceuticals demonstrates strong growth potential, driven by its innovative Cu-SAR-bisPSMA platform for prostate cancer treatment. Recent trial advancements show promising efficacy and safety, with significant PSA reductions in heavily pre-treated participants. The FDA's Fast Track Designation supports accelerated development. Despite a net loss of A$23.58 million for the half-year ending December 2024, revenue grew to A$10.94 million from A$6.52 million year-over-year, with forecasts indicating rapid revenue growth exceeding market averages.</p><ul><li>Take a closer look at Clarity Pharmaceuticals' potential here in our earnings growth report.</li><li>Our valuation report here indicates Clarity Pharmaceuticals may be overvalued.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f738db8-37ac-4398-b17d-c71a9e354b96/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f738db8-37ac-4398-b17d-c71a9e354b96/chart/earnings-and-revenue-growth"/><figcaption>ASX:CU6 Earnings and Revenue Growth as at Apr 2025</figcaption></figure><h2>IperionX (ASX:IPX)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p><p><strong>Overview:</strong> IperionX Limited is involved in the exploration and development of mineral properties in the United States, with a market capitalization of approximately A$900.03 million.</p><p><strong>Operations:</strong> IperionX Limited's revenue segments are not specified in the provided text.</p><p><strong>Insider Ownership:</strong> 19.2%</p><p>IperionX is poised for significant growth, driven by its Titan Critical Minerals Project in Tennessee and strategic U.S. partnerships, including a USD 47.1 million government award to enhance the titanium supply chain. Despite recent shareholder dilution and a net loss of USD 16.24 million for the half-year ending December 2024, IperionX's revenue is forecast to grow rapidly, outpacing market averages with expected profitability within three years, supported by innovative technologies and substantial insider ownership.</p><ul><li>Click here to discover the nuances of IperionX with our detailed analytical future growth report.</li><li>Our comprehensive valuation report raises the possibility that IperionX is priced higher than what may be justified by its financials.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e8dfcb7-c0e0-4531-b20e-c5e49bcf6fb0/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e8dfcb7-c0e0-4531-b20e-c5e49bcf6fb0/chart/ownership-breakdown"/><figcaption>ASX:IPX Ownership Breakdown as at Apr 2025</figcaption></figure><h2>Where To Now?</h2><ul><li>Click through to start exploring the rest of the 90  Fast Growing ASX Companies With High Insider Ownership now.</li><li>Contemplating Other Strategies? This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders.      It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities.      All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p><div><p>If you're looking to trade IperionX, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p><p><span>Sponsored Content</span></p></div></div></div>

<p>The Australian market is currently facing slower trade and investor caution due to global tensions. Identifying growth companies with significant insider ownership can provide investment insights. Notable companies include Aurelia Metals (23.9% insider ownership, 23.6% earnings growth), Clarity Pharmaceuticals (17.8% insider ownership, rapid revenue growth), and IperionX (19.2% insider ownership, expected profitability within three years). These companies show promise despite recent challenges, with insider ownership indicating confidence in their long-term prospects.</p>

3 ASX Growth Companies With Up To 23% Insider Ownership